Jeong Hejin, Shaia Jacqueline K, Talcott Katherine E, Singh Rishi P
Ophthalmic Surg Lasers Imaging Retina. 2024 Dec;55(12):706-713. doi: 10.3928/23258160-20240729-03. Epub 2024 Aug 1.
As the therapeutic efficacy of lipid-lowering agents (LLA) against diabetic retinopathy (DR) remains controversial, this study aimed to evaluate whether various LLA therapies are associated with a reduced risk of DR progression.
This retrospective study of the medical records of adults with type 2 diabetes mellitus and DR compared the risk of adverse progression of DR between patients who received statins, fibrates, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, and no LLA (control).
Patients in the statin cohort had a reduced rate of progression to proliferative DR compared to controls (HR = 0.30, CI = 0.11 to 0.83). The PCSK9 inhibitor cohort had a reduced risk of progressing to other secondary complications of DR compared to the control (RR = 0.52, CI = 0.43 to 0.64), statin (RR = 0.69, CI = 0.61 to 0.79), and fibrate (RR = 0.67, CI = 0.59 to 0.77) cohorts.
These findings suggest use of statins and PCSK9 inhibitors are associated with a reduced risk of adverse progression of DR. .
由于降脂药物（LLA）治疗糖尿病视网膜病变（DR）的疗效仍存在争议，本研究旨在评估各种LLA治疗是否与降低DR进展风险相关。
这项对2型糖尿病和DR成年患者病历的回顾性研究，比较了接受他汀类药物、贝特类药物、前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂治疗的患者与未接受LLA治疗（对照组）的患者发生DR不良进展的风险。
与对照组相比，他汀类药物组患者进展为增殖性DR的发生率降低（风险比[HR]=0.30，可信区间[CI]=0.11至0.83）。与对照组、他汀类药物组（RR=0.69，CI=0.61至0.79）和贝特类药物组（RR=0.67，CI=0.59至0.77）相比，PCSK9抑制剂组进展为DR其他继发并发症的风险降低。
这些发现表明，使用他汀类药物和PCSK9抑制剂与降低DR不良进展风险相关。
